Efficacy of Polypodium leucotomos in pediatric patients with Xeroderma Pigmentosum
Authors
-
Iris Alvarez - Montiel
Universidad Nacional Autónoma de Honduras (UNAH),. Tegucigalpa, Honduras
https://orcid.org/0009-0003-3528-2650
-
Maria Félix Rivera
Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras
https://orcid.org/0000-0003-4432-2696
DOI:
https://doi.org/10.70099/BJ/2024.01.01.25Keywords:
Langerhans cells, Polypodium leucotomus, Xeroderma PigmentosumAbstract
Background: Xeroderma pigmentosum (XP) is a photosensitive genodermatotic to ultraviolet radiation, producing irreparable damage to DNA favoring carcinogenesis. Polypodium leucotomos (PL) decreases DNA mutation and improves carcinogenesis and immunosuppression by preserving Langerhans cells; there are no studies on using PL in patients with XP. Objective: To evaluate the efficacy of PL when comparing the incidence of cancer and improving immunosuppression in pediatric patients with XP through the differences in the measurement of Langerhans cells (CD1a) Methodology: A prospective, quasi-experimental study of one arm was carried out in 8 pediatric patients with a clinical diagnosis of XP at Hospital María Especialidades Pediatricas (HMEP) Tegucigalpa, Honduras (August 2017 - August 2018). PL 7.5 mg/kg was given in 2 doses for 1 year, and 2 separate measurements were made during this time. Results: We found 75% of the patients were women, clinically 62.5% were found in phase III or tumor; the main skin manifestations were hyperpigmentation, hypopigmentation and xerosis in 100% of the patients; photophobia and conjunctivitis in 100% and 87% of the cases. Significant differences were found in Langerhans cell measurements before (A) and after (B) the use of the PL extract, between epidermis A with a p-value of 0.029 and in dermis A and B with a p-value of (0.005 and 0.007), respectively. (p<0.05). Only 2 patients reported abdominal pain at the beginning of the study. Conclusion: Oral administration of PL demonstrated efficacy in pediatric patients with XP, as it preserves Langerhans cells, improves immunosuppression, and decreases carcinogenesis; it can be considered a preventive and palliative therapeutic alternative.
References
1. Martens Marie C, Emmert Steffen and Boeckmann Lars, Xeroderma Pigmentosum: Gene Variants and Splice Variants. Genes (Basel). 2021 Aug; 12(8): 1173
2. Leung Alexander, KC Leung, Barankin Benjamin, Lam Joseph M, Leong Kin F, Lun Hon K. Xeroderma pigmentosum: an updated review. DrugsContext. 2022 April 25; 11:2022-2-5.
3. Dupuy Aurelie, Sarasina Alain. DNA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease. MutationResearch, 2015, 776 () 2–8
4. Pinto Christopher, Nayyar Rajest, Asvita Dandamudi, Chirumamilla Avinash, Patel Prachi. Late Presentation of Xeroderma Pigmentosa With Squamous Cell Carcinoma in Septic Shock: Report of a Rare Case. Cureus. 2022 Jun; 14(6): e25967
5. Brambullo Tito, Colonna Michele R, VindigniVincenzo, Piaserico Stefano, Masciopinto Giuseppe, Galeano Mariarosaria, et al. Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated—A Systematic Review. Biomed Res Int. 2022; 2022: 8549532
6. NishigoriChikako, NakanoEiji, Masaki Taro, OnoRyusuke, Takeuchi Seiji, TsujimotoMariko, et al. Characteristics of Xeroderma Pigmentosum in Japan: Lessons From Two Clinical Surveys and Measures for Patient Care. Fotoquímica y Fotobiología, 2019, 95: 140–153
7. Yuan Ling, Cui Dan, Zhao Er-Jiang, Jia Chen-Zhi, Wang Li-Dong, Lu Wei-Quan. XPD Lys751. Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls. World J Gastroenterol. 2011 May 14;17(18):2343-8.
8. YousafSajeela, Khan Mohamed I, Michael Shazia, Akhtar Farah, Ali Syeda H, RiazMoeen, et al. XRCC1 and XPD DNA repair gene polymorphisms: a potential risk factor for glaucoma in the Pakistani population. Mol Vis. 2011; 17:1153-63.
9. Bhatia Neal. Polypodium leucotomos: a potential new photoprotective agent. Am J ClinDermatol. 2015; 16(2):73-9.
10. Palomino Olga M. Current knowledge in Polypodium leucotomos effect on skin protection. ArchDermatol Res. 2015; 307(3):199-209.
11. Rodríguez-García R, Aguilar-Ye A, Puig-Sosa PJ, Solis-Daun O, Padilla-Castillo A. Xerodermapigmentoso en dos hermanas. Rev Mex Pediatr 2002; 69(4); 151-154.
12. Black Jennifer O. Xeroderma Pigmentosum. Head and Neck Pathol, 2016, 10:139–144
13. Hernández Cibrián; Sutherland Nelson; Etnobotánica de los Helechos de Honduras. Ceiba, 2007. Volumen 48(1-2):1-10
14. Cambar, Pablo Jose. Algunos estudios farmacológicos de las plantas medicinales en Honduras. Revista medica Hondureña.– 1985, Vol. 53; 190-196
15. Segars, Kelly, McCarver Victoria, Miller Richard A. Dermatologic Applications of Polypodium leucotomos: A Literature Review. J Clin AesthetDermatol. 2021 Feb; 14(2): 50–60
16. Middelkamp-Hup Maritza A, PathakMadhu A, Parrado Concepción, García-Caballero Tomas, Rius-Díaz Francisca, Fitzpatrick Thomas B, González Salvador. Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad Dermatol. 2004;50(1):41–49.
17. Del Rosso, James. Polypodium Leucotomos Extract (PLE): New Study Gives Evidence-based Insight into “Ain’t Nothing Like the Real Thing”. J Clin AesthetDermatol. 2019 agosto; 12(8): 45–46
18. Middelkamp-Hup Maritza A, Pathak Madhu A, Parrado Concepcion, Goukassian David, Rius-Díaz Francisca, Mihm Martín C, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004;51(1):910–918
19. Kohli I Indermeet, Shafi Rubina, IsedehPrescilia, Griffith James, Al-Jamal Mohammed S, Silpa-Archa Narumol. The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study. J Am Acad Dermatol. 2017;77(1):33–41. e1.
20. Mahamat-Saleh Y, Aune Dagfinn, Schlesinger Sabrina. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose–response meta-analysis of prospective studies Sci Rep. 2020; 10: 13151.
21. Halkud R, Shenoy AM, Naik SM, Chavan P, Sidappa KT, Biswas S. Xeroderma pigmentosum: clinicopathological review of the multiple oculocutaneous malignancies and complications. Indian J Surg Oncol. 2014 Jun;5(2):120-4.
22. Martens, M.C.; Emmert, S.; Boeckmann, L. Xeroderma Pigmentosum: Gene Variants and Splice Variants. Genes 2021, 12, 1173.
23. Rodríguez-Luna A, Zamarrón A, Juarranz Á, González S. Clinical Applications of Polypodium leucotomos (Fernblock®): An Update. Life (Basel). 2023 Jul 5;13(7):1513.
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
